NCT00004143View on ClinicalTrials.gov

Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies & Bone Marrow Failure Syndromes

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 1999

Primary Completion Date

May 31, 2008

Study Completion Date

June 30, 2009

Conditions

Sickle Cell AnemiaSevere Aplastic AnemiaParoxysmal Nocturnal Hemoglobinuria (PNH)Pure Red Cell Aplasia

Interventions

DRUG

Campath, Chemo and/or TBI Allo SCT

Allogeneic PBSC/marrow will be collected/harvested from the donor after granulocyte colony-stimulating factor (G-CSF) priming. The allogeneic PBSCs will be infused as per current institutional practice.

Trial Locations (2)

27710

Duke Cancer Institute, Durham

32804

Florida Hospital Cancer Institute, Orlando

All Listed Sponsors

lead

David Rizzieri, MD

OTHER

NCT00004143 - Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies & Bone Marrow Failure Syndromes | Biotech Hunter | Biotech Hunter